

Elinor Ben-Menachem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/413861/publications.pdf>

Version: 2024-02-01

118
papers

8,640
citations

53794

45
h-index

45317

90
g-index

119
all docs

119
docs citations

119
times ranked

6070
citing authors

#	ARTICLE	IF	CITATIONS
1	ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. <i>Epilepsia</i> , 2006, 47, 1094-1120.	5.1	782
2	Updated <sc>ILAE</sc> evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. <i>Epilepsia</i> , 2013, 54, 551-563.	5.1	599
3	Vagus-nerve stimulation for the treatment of epilepsy. <i>Lancet Neurology</i> , The, 2002, 1, 477-482.	10.2	503
4	Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partialâ€œOnset Seizures. <i>Epilepsia</i> , 2007, 48, 1308-1317.	5.1	435
5	Pregabalin Pharmacology and Its Relevance to Clinical Practice. <i>Epilepsia</i> , 2004, 45, 13-18.	5.1	432
6	Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Doubleâ€œBlind, Responderâ€œSelected Study Evaluating Monotherapy. <i>Epilepsia</i> , 2000, 41, 1276-1283.	5.1	371
7	Vagus Nerve Stimulation, Side Effects, and Long-Term Safety. <i>Journal of Clinical Neurophysiology</i> , 2001, 18, 415-418.	1.7	321
8	Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase <sc>III</sc> studies. <i>Epilepsia</i> , 2013, 54, 1481-1489.	5.1	235
9	Double-Blind, Placebo-Controlled Trial of Topiramate as Add-on Therapy in Patients with Refractory Partial Seizures. <i>Epilepsia</i> , 1996, 37, 539-543.	5.1	227
10	Surgically implanted and nonâ€œinvasive vagus nerve stimulation: aâ€œreview of efficacy, safety and tolerability. <i>European Journal of Neurology</i> , 2015, 22, 1260-1268.	3.3	223
11	Weight issues for people with epilepsyâ€œA review. <i>Epilepsia</i> , 2007, 48, 42-45.	5.1	205
12	Levetiracetam: treatment in epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2079-2088.	1.8	186
13	Pharmacokinetics of Levetiracetam during Pregnancy, Delivery, in the Neonatal Period, and Lactation. <i>Epilepsia</i> , 2007, 48, 1111-1116.	5.1	185
14	Vigabatrin: 2008 Update. <i>Epilepsia</i> , 2009, 50, 163-173.	5.1	183
15	New Antiepileptic Drugs: Comparison of Key Clinical Trials. <i>Epilepsia</i> , 1999, 40, 590-600.	5.1	180
16	Predictors of Weight Loss in Adults with Topiramateâ€œTreated Epilepsy. <i>Obesity</i> , 2003, 11, 556-562.	4.0	176
17	Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. <i>Epilepsy Research</i> , 2003, 57, 1-13.	1.6	136
18	Complications and safety of vagus nerve stimulation: 25 years of experience at a single center. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 18, 97-104.	1.3	119

#	ARTICLE	IF	CITATIONS
19	Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure: the Journal of the British Epilepsy Association, 2003, 12, 131-135.	2.0	111
20	Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Research, 1998, 29, 109-114.	1.6	107
21	Vigabatrin Visual Toxicity: Evolution and Dose Dependence. Epilepsia, 2001, 42, 609-615.	5.1	103
22	Perampanel, a selective, noncompetitive α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307. Epilepsia, 2013, 54, 126-134.	5.1	103
23	Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia, 2014, 55, 1058-1068.	5.1	99
24	Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology, 2016, 87, 314-323.	1.1	95
25	Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurologica Scandinavica, 2011, 124, 5-15.	2.1	91
26	Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Epilepsy Research, 2000, 40, 33-39.	1.6	89
27	Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia, 2013, 54, 98-107.	5.1	85
28	Novel Mechanisms of Action of Three Antiepileptic Drugs, Vigabatrin, Tiagabine, and Topiramate. Neurochemical Research, 2003, 28, 333-340.	3.3	81
29	Topiramate reduces AMPA-induced Ca^{2+} transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. Journal of Neurochemistry, 2005, 94, 1124-1130.	3.9	80
30	Examining the Clinical Utility of Lacosamide. CNS Drugs, 2010, 24, 1041-1054.	5.9	77
31	Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Research, 2003, 53, 57-64.	1.6	74
32	Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study. Epilepsy Research, 2013, 103, 262-269.	1.6	74
33	Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. Epilepsia, 2018, 59, 866-876.	5.1	74
34	Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. Journal of Neurochemistry, 2004, 88, 320-325.	3.9	73
35	Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy and Behavior, 2010, 18, 24-30.	1.7	73
36	Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology, 2002, 59, S44-7.	1.1	70

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study. <i>Epilepsia</i> , 2018, 59, 479-491.	5.1	69
38	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. <i>Epilepsia</i> , 2018, 59, 1727-1739.	5.1	67
39	Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. <i>Epilepsia</i> , 2010, 51, 951-957.	5.1	65
40	Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. <i>Epilepsy Research</i> , 1992, 11, 45-49.	1.6	63
41	The evolution of antiepileptic drug development and regulation. <i>Epileptic Disorders</i> , 2010, 12, 3-15.	1.3	60
42	Obstetric risks for women with epilepsy during pregnancy. <i>Epilepsy and Behavior</i> , 2007, 11, 283-291.	1.7	57
43	Levetiracetam reduces caffeine-induced Ca ²⁺ transients and epileptiform potentials in hippocampal neurons. <i>NeuroReport</i> , 2003, 14, 471-475.	1.2	56
44	Perampanel for adjunctive treatment of partial-onset seizures: A pooled dose-response analysis of phase III studies. <i>Epilepsia</i> , 2014, 55, 423-431.	5.1	56
45	Medical management of refractory epilepsy—Practical treatment with novel antiepileptic drugs. <i>Epilepsia</i> , 2014, 55, 3-8.	5.1	53
46	Topiramate monotherapy in epilepsy and migraine prevention. <i>Clinical Therapeutics</i> , 2005, 27, 154-165.	2.5	45
47	Increased vulnerability of the blood-brain barrier to acute hypertension following depletion of brain noradrenaline. <i>Journal of Neural Transmission</i> , 1982, 53, 159-167.	2.8	44
48	Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. <i>Epilepsy and Behavior</i> , 2014, 41, 164-170.	1.7	43
49	Lacosamide: An investigational drug for adjunctive treatment of partial-onset seizures. <i>Drugs of Today</i> , 2008, 44, 35.	1.1	43
50	Pharmacokinetic Effects of Vigabatrin on Cerebrospinal Fluid Amino Acids in Humans. <i>Epilepsia</i> , 1989, 30, S12-4.	5.1	41
51	Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures. <i>Epilepsy Research</i> , 2003, 54, 63-71.	1.6	36
52	Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. <i>Clinical Therapeutics</i> , 2008, 30, 1180-1195.	2.5	36
53	Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine. <i>Epilepsy Research</i> , 1990, 6, 134-140.	1.6	34
54	Radiation of the Rat Brain Suppresses Seizure-Induced Neurogenesis and Transiently Enhances Excitability during Kindling Acquisition. <i>Epilepsia</i> , 2007, 48, 1952-1963.	5.1	34

#	ARTICLE	IF	CITATIONS
55	A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. <i>Epilepsia</i> , 2011, 52, 816-825.	5.1	34
56	Neurostimulation—Past, Present, and Beyond. <i>Epilepsy Currents</i> , 2012, 12, 188-191.	0.8	34
57	Cannabinoids for epilepsy: What do we know and where do we go?. <i>Epilepsia</i> , 2018, 59, 291-296.	5.1	32
58	Cardiovascular fitness and later risk of epilepsy. <i>Neurology</i> , 2013, 81, 1051-1057.	1.1	29
59	Airway effects of direct left-sided cervical vagal stimulation in patients with complex partial seizures. <i>Epilepsy Research</i> , 1994, 18, 149-154.	1.6	26
60	Responsive neurostimulation—modulating the epileptic brain. <i>Nature Reviews Neurology</i> , 2014, 10, 247-248.	10.1	26
61	Vagal Blocking for Obesity Control: a Possible Mechanism-Of-Action. <i>Obesity Surgery</i> , 2017, 27, 177-185.	2.1	26
62	A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. <i>CNS Drugs</i> , 2020, 34, 661-672.	5.9	25
63	Management of Focal-Onset Seizures. <i>Drugs</i> , 2006, 66, 1701-1725.	10.9	20
64	Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. <i>Epilepsia</i> , 2019, 60, 2437-2447.	5.1	20
65	Recent advances in the diagnosis and treatment of epilepsy. <i>European Journal of Neurology</i> , 2001, 8, 519-539.	3.3	19
66	Vigabatrin therapy for refractory complex partial seizures: review of major European trials. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 16-28.	2.1	19
67	Estimating Long-Term Vagus Nerve Stimulation Effectiveness: Accounting for Antiepileptic Drug Treatment Changes. <i>Neuromodulation</i> , 2018, 21, 797-804.	0.8	18
68	Efficacy of Nafimidone in the Treatment of Intractable Partial Seizures: Report of a Two-Center Pilot Study. <i>Epilepsia</i> , 1985, 26, 607-611.	5.1	17
69	Expanding Antiepileptic Drug Options: Clinical Efficacy of New Therapeutic Agents. <i>Epilepsia</i> , 1996, 37, S4-S7.	5.1	17
70	Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system—a case study. <i>Epilepsy Research</i> , 1993, 16, 241-243.	1.6	16
71	Vagus Nerve Stimulation for Treatment of Seizures?. <i>Archives of Neurology</i> , 1998, 55, 231.	4.5	16
72	Preliminary experience with a new system for vagus nerve stimulation for the treatment of refractory focal onset seizures. <i>Epilepsy and Behavior</i> , 2013, 29, 416-419.	1.7	16

#	ARTICLE	IF	CITATIONS
73	New antiepileptic drugs and non-pharmacological treatments. <i>Current Opinion in Neurology</i> , 2000, 13, 165-170.	3.6	14
74	Inhibition of Carbamazepine and Phenytoin Metabolism by Nafimidone, a New Antiepileptic Drug. <i>Epilepsia</i> , 1987, 28, 699-705.	5.1	13
75	Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures. <i>Epilepsy and Behavior</i> , 2018, 82, 119-127.	1.7	13
76	A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy. <i>Epilepsy and Behavior</i> , 2022, 126, 108483.	1.7	13
77	Is Prolactin a Clinically Useful Measure of Epilepsy?. <i>Epilepsy Currents</i> , 2006, 6, 78-79.	0.8	11
78	Eslicarbazepine Acetate: A Well-Kept Secret?. <i>Epilepsy Currents</i> , 2010, 10, 7-8.	0.8	11
79	Guidelines?Are They Useful?. <i>Epilepsia</i> , 2006, 47, 62-64.	5.1	10
80	Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trial. <i>Epilepsia Open</i> , 2021, 6, 618-623.	2.4	10
81	Randomized controlled trial of moderate cardiovascular exercise for patients with drug-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2021, 124, 108335.	1.7	10
82	Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. <i>Epilepsy Research</i> , 2021, 170, 106526.	1.6	10
83	Topiramate: current status and therapeutic potential. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 1085-1094.	4.1	9
84	Diagnosis and Treatment of Partial Seizures. <i>CNS Drugs</i> , 1999, 11, 23-39.	5.9	9
85	Neurostimulation for epilepsy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 108, 955-970.	1.8	9
86	Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs. <i>Epilepsy Research</i> , 2018, 141, 83-89.	1.6	9
87	Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 397-404.	2.1	9
88	Effect of Î³-Vinyl GABA on Interictal Spikes and Sharp Waves in Patients with Intractable Complex Partial Seizures. <i>Epilepsia</i> , 1989, 30, 79-83.	5.1	8
89	Effect of levetiracetam on hippocampal protein expression and cell proliferation in rats. <i>Epilepsy Research</i> , 2010, 90, 110-120.	1.6	8
90	Overcoming Barriers to Successful Epilepsy Management. <i>Epilepsy Currents</i> , 2012, 12, 158-160.	0.8	8

#	ARTICLE	IF	CITATIONS
91	A prospective, randomized, multicentre trial for the treatment of refractory status epilepticus; experiences from evaluating the effect of the novel drug candidate, NS1209. <i>Epilepsy Research</i> , 2013, 106, 292-295.	1.6	8
92	Preliminary efficacy of levetiracetam in monotherapy. <i>Epileptic Disorders</i> , 2003, 5 Suppl 1, S51-5.	1.3	8
93	VNS Therapy versus the latest antiepileptic drug. <i>Epileptic Disorders</i> , 2005, 7 Suppl 1, S22-6.	1.3	8
94	Strategy for utilization of new antiepileptic drugs. <i>Current Opinion in Neurology</i> , 2008, 21, 167-172.	3.6	7
95	Foreword. <i>CNS Drugs</i> , 2011, 25, 1-2.	5.9	7
96	Vaccination and the Onset of Dravet Syndrome. <i>Epilepsy Currents</i> , 2011, 11, 120-122.	0.8	5
97	Highlights From the Annual Meeting of the American Epilepsy Society 2018. <i>Epilepsy Currents</i> , 2019, 19, 152-158.	0.8	5
98	Retigabine: Has the Orphan Found a Home?. <i>Epilepsy Currents</i> , 2007, 7, 153-154.	0.8	4
99	Toward a More Pragmatic View of Driving and Epilepsy. <i>Epilepsy Currents</i> , 2004, 4, 133-134.	0.8	3
100	Vigabatrin's Complicated Journey—To be or Not to Be?. <i>Epilepsy Currents</i> , 2009, 9, 130-132.	0.8	3
101	Introduction—Annual Course 2008: American Epilepsy Society. <i>Epilepsia</i> , 2009, 50, 1-2.	5.1	3
102	Eslicarbazepine acetate for the treatment of partial epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1165-1169.	1.8	3
103	Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18–59 years) adults. <i>Epilepsy Research</i> , 2021, 169, 106478.	1.6	3
104	Infantile Spasms and Epilepsy Currents. <i>Epilepsy Currents</i> , 2005, 5, 157-158.	0.8	2
105	AAN/AES Guidelines on Use of New AEDS. <i>Epilepsy Currents</i> , 2005, 5, 30-32.	0.8	2
106	Epilepsy as a Warning Sign for Stroke. <i>Epilepsy Currents</i> , 2005, 5, 42-43.	0.8	2
107	The Importance of Increased Clearance of Lamotrigine during Pregnancy. <i>Epilepsy Currents</i> , 2005, 5, 59-60.	0.8	2
108	Seizure Aggravation—Evidence that Oxcarbazepine Requires Monitoring. <i>Epilepsy Currents</i> , 2008, 8, 93-95.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Vasoactive intestinal polypeptide (VIP) in cerebrospinal fluid from men after long-term exposure to organic solvents. <i>Acta Neurologica Scandinavica</i> , 2009, 70, 317-318.	2.1	2
110	Treating epileptic emergencies – pharmacological advances. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2227-2234.	1.8	2
111	Proof of efficacy trials: seizure types. <i>Epilepsy Research</i> , 2001, 45, 31-34.	1.6	1
112	Sudden Death and Epilepsy. <i>Epilepsy Currents</i> , 2005, 5, 223-224.	0.8	1
113	Is Topiramate Tops?. <i>Epilepsy Currents</i> , 2008, 8, 60-61.	0.8	1
114	Outcomes Remain Ambivalent for Deep Brain Stimulation and Epilepsy. <i>Epilepsy Currents</i> , 2008, 8, 121-123.	0.8	1
115	Commentary: ILAE Definition of Epilepsy. <i>Epilepsia</i> , 2014, 55, 486-487.	5.1	1
116	A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel. <i>Epilepsy Research</i> , 2021, 174, 106649.	1.6	1
117	Cenobamate as adjunctive therapy in adults with uncontrolled focal seizures: Time to onset of efficacy during titration. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119097.	0.6	0
118	Safety of cenobamate as adjunctive therapy in adults with uncontrolled focal seizures: Time to onset, duration, and severity of the most common adverse events. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119099.	0.6	0